Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FCGR3A 2214 ETANERCEPT CHEMBL1201572 DrugBank 15526004, 15457442
FCGR3A 2214 GEMTUZUMAB OZOGAMICIN CHEMBL1201506 DrugBank 17139284, 17016423, 7509291
FCGR3A 2214 IBRITUMOMAB TIUXETAN CHEMBL1201606 DrugBank 17139284, 17016423
FCGR3A 2214 PALIVIZUMAB CHEMBL1201586 DrugBank 17139284, 17016423
FCGR3A 2214 DACLIZUMAB CHEMBL1201605 DrugBank 17139284, 17016423
FCGR3A 2214 TESMILIFENE HYDROCHLORIDE CHEMBL2107467 NCI 11556524
FCGR3A 2214 PUROMYCIN CHEMBL469912 NCI 8423352
FCGR3A 2214 THALIDOMIDE CHEMBL468 NCI 15457133
FCGR3A 2214 VINCRISTINE CHEMBL90555 PharmGKB
FCGR3A 2214 ALEMTUZUMAB CHEMBL1201587 DrugBank 15217834
FCGR3A 2214 EFALIZUMAB CHEMBL1201575 DrugBank 17139284, 17016423
FCGR3A 2214 BEVACIZUMAB CHEMBL1201583 DrugBank 17139284, 17016423
FCGR3A 2214 DOXORUBICIN CHEMBL53463 NCI 1830717
FCGR3A 2214 HYDROGEN PEROXIDE CHEMBL71595 NCI 2138680
FCGR3A 2214 HEPARIN CHEMBL1909300 NCI 18492254
FCGR3A 2214 CHEMBL411250 CHEMBL411250 NCI 1827816
FCGR3A 2214 INDOMETHACIN CHEMBL6 NCI 17329922
FCGR3A 2214 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 1827816
FCGR3A 2214 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
FCGR3A 2214 INFLIXIMAB CHEMBL1201581 PharmGKB
FCGR3A 2214 BASILIXIMAB CHEMBL1201439 DrugBank 17139284, 17016423
FCGR3A 2214 ALEFACEPT CHEMBL1201571 DrugBank 12795239, 17139284, 17016423, 11970990
FCGR3A 2214 NATALIZUMAB CHEMBL1201607 DrugBank 17139284, 17016423
FCGR3A 2214 CHONDROITIN SULFATE CHEMBL2303614 NCI 18006074
FCGR3A 2214 PENICILLIN G POTASSIUM CHEMBL1223 NCI 17257217
FCGR3A 2214 SODIUM CHLORIDE CHEMBL1200574 NCI 17187818
FCGR3A 2214 CETUXIMAB CHEMBL1201577 PharmGKB, NCI, DrugBank 17139284, 17016423, 17704420
FCGR3A 2214 GLOBULIN, IMMUNE CHEMBL1201599 antagonist DrugBank 20441428, 17911465, 17351760
FCGR3A 2214 ADALIMUMAB CHEMBL1201580 DrugBank 17139284, 17016423
FCGR3A 2214 ABCIXIMAB CHEMBL1201584 DrugBank 17139284, 17016423
FCGR3A 2214 RITUXIMAB CHEMBL1201576 PharmGKB, DrugBank 15448014, 16609067, 17324336
FCGR3A 2214 MUROMONAB-CD3 CHEMBL1201608 NCI, DrugBank 11599102, 17139284, 17016423
FCGR3A 2214 TOSITUMOMAB CHEMBL1201604 DrugBank 17139284, 17016423
FCGR3A 2214 CIMETIDINE CHEMBL30 NCI 11556524
FCGR3A 2214 PREDNISOLONE CHEMBL131 NCI 17329922
FCGR3A 2214 BROMOACETIC ACID CHEMBL60851 NCI 1832500
FCGR3A 2214 CYCLOSPORINE CHEMBL160 NCI 17852453
FCGR3A 2214 EPOETIN ALFA CHEMBL1201565 NCI 1300984
FCGR3A 2214 PENICILLIN G SODIUM CHEMBL1126 NCI 1371977
FCGR3A 2214 DIMETHYL SULFOXIDE CHEMBL504 NCI 16896803
FCGR3A 2214 GELDANAMYCIN CHEMBL278315 NCI 7662976
FCGR3A 2214 LACTULOSE HYDRATE CHEMBL1237068 NCI 1418064
FCGR3A 2214 MAFOSFAMIDE CHEMBL59990 NCI 1515095
FCGR3A 2214 TRASTUZUMAB CHEMBL1201585 PharmGKB, NCI, DrugBank 17363544, 18089830
FCGR3A 2214 CYTARABINE CHEMBL803 NCI 17852453
FCGR3A 2214 RIZATRIPTAN CHEMBL905 NCI 10729215
FCGR3A 2214 FENTANYL CHEMBL596 NCI 11772808

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FCGR3A rs396991 CC rituximab efficacy yes Patients with the CC genotype were more likely to have a good/moderate response to rituximab treatment at 6 months, as compared to those with the AC or AA genotype. No significant result was seen at 4 months. Additionally, those with the CC genotype were less likely to stop responding to rituximab treatment between months 4 and 6 of treatment, as compared to those with the AC or AA genotype. The European League Against Rheumatism (EULAR) response criteria used, by means of DAS28 using erythrocyte sedimentation rate. Note that there was a significant difference in baseline DAS28 score between those with the CC genotype and those with the AA genotype (p = 0.01). Genotype CC is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AC. 23505228 1184510363
FCGR3A rs396991 CC trastuzumab efficacy no (trend) Genotype CC is associated with increased response to trastuzumab in women with Breast Neoplasms as compared to genotypes AA + AC. 21109570 827825747
FCGR3A rs396991 AA adalimumab efficacy no After 12 weeks of treatment, no significant differences in mean percentage Psoriasis Area and Severity Index (PASI) improvement, percentage of patients with an improvement of PASI of at least 75%, percentage of patients with a worsening of PASI or an improvement of less than 50%, or PASI after 12 weeks of treatment were seen between the genotypes. Genotype AA is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC. 24048425 1183699556
FCGR3A rs396991 CC trastuzumab efficacy yes The response rate for 158 V/V and patients with either 158 V/F or 158 F/F genotype are 82%, 42% and 35%, respectively. Genotype CC is associated with increased response to trastuzumab in people with Breast Neoplasms as compared to genotypes AA + AC. 18347005 1185003533
FCGR3A rs396991 CC adalimumab efficacy no in a meta-analysis of seven studies. Genotype CC is not associated with response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AC. 25823782 1447944960
FCGR3A rs396991 C Tumor necrosis factor alpha efficacy yes This was only significant in patients with follow-up times greater than or equal to 6 months. Association is given for the V allele. Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic, Crohn Disease, Psoriasis or Spondylitis, Ankylosing as compared to allele A. 27490376 1448259006
FCGR3A rs396991 AC + CC Tumor necrosis factor alpha efficacy yes Moderate to severe chronic plaque psoriasis. Responders were defined as those with a change in the Psoriasis Area and Severity Index (PASI) of >75%, while non-responders were defined as those with a change in PASI of <=50%, after 6 months of therapy. This association was attributed specifically to treatment with etanercept, as no association was found with infliximab + adalimumab (p=0.331). Please note that alleles have been complemented to the plus chromosomal strand. Genotypes AC + CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA. 27044681 1448426950
FCGR3A rs396991 C cetuximab efficacy no Overall survival and progression-free survival were used as indicators of response to cetuximab. Allele C is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele A. 30318772 1449752269
FCGR3A rs396991 AA tocilizumab efficacy yes The AA genotype was associated with an increased EULAR response at 12 months of treatment with tocilzumab, but not at 6 months or 18 months of treatment. Please note that alleles have been complemented to the positive strand. Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AC + CC. 30457672 1450371553
FCGR3A rs396991 AC + CC rituximab efficacy yes Presence of the C allele was associated with an improved low disease activity rate and an improvement in DAS28 at 18 months of treatment, but not at 6 or 12 months of treatment. Please note that alleles have been complemented to the positive strand. Genotypes AC + CC are associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA. 30457672 1450371570
FCGR3A rs396991 A infliximab efficacy yes Patient categorized as being a good or moderate responder (responder), or a non-responder according to EULAR response criteria at 22 weeks. The authors note that the distribution of genotypes was significantly different between patients with regard to response, however they do not give a direction to the association. Data from their table suggest that the AA genotype MAY be associated with response to infliximab. Distribution as follows: Responder - AA=20, AC=7, CC=0; Non-responder - AA=0, AC=1, CC=1. Allele A is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to allele C. 19005160 769171565
FCGR3A rs396991 A cetuximab efficacy yes The F allele carriers was also associated with longer progression-free survival. Allele A is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to allele C. 17704420 769171568
FCGR3A rs396991 AA adalimumab efficacy yes Patients with the AA genotype had a higher psoriasis body surface area (BSA) after 6-8 weeks of treatment, as compared to those with the AC or CC genotype. No significant difference in psoriasis BSA were seen after 12 weeks of treatment. Additionally, no significant differences between these genotype groups were seen when considering the mean percentage psoriasis body surface area (BSA) improvement over 12 weeks. Genotype AA is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC. 24048425 1183699550
FCGR3A rs396991 AA rituximab efficacy yes Presented as FCGR3A-V158F. The FCGR3A-158F allele was associated with a risk of insufficient memory B-cell depletion and a short retreatment interval during the initial 2 years. In terms of clinical response, the FCGR3A-158F allele was associated with a risk of at least 1 relapse while receiving rituximab treatment but no association was observed between the FCGR3A genotype and more than 2 relapses post-ARR or EDSS worsening. Genotype AA is associated with decreased response to rituximab in people with Neuromyelitis Optica as compared to genotype CC. 26167726 1447679904
FCGR3A rs396991 C cetuximab efficacy no Meta-analysis with 15 studies. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Please note that alleles have been complemented to the plus chromosomal strand. Allele C is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A. 27897268 1449165380
FCGR3A rs396991 AA cetuximab efficacy yes ONLY significant when combined in an analysis with rs1801274. The median progression-free survival time for patients with the rs1801274 GG genotype and/or the rs396991 TT genotype was significantly longer as compared with carriers of rs1801274 A allele and/or rs396991 C allele (5.5 vs 4.1 months). This association remained significant in Cox multivariate analysis. However, on its own, this SNP was NOT significantly associated with progression-free survival time. Patients received polychemotherapy with cisplatin or carboplatin, fluorouracil and cetuximab and had metastatic squamous cell head and neck cancer. Please note that alleles have been complemented to the plus chromosomal strand. Genotype AA is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AC + CC. 28719596 1449154943